TWA
DNLI icon

TCI Wealth Advisors’s Denali Therapeutics DNLI Stock Holding History

TCI Wealth Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-114
Closed -$3K – 2317
2022
Q2 		$3K Sell
114
-182
-61% -$4.77K ﹤0.01% 1777
2022
Q1 		$10K Buy
296
+80
+37% +$2.75K ﹤0.01% 1085
2021
Q4 		$10K Buy
216
+59
+38% +$2.79K ﹤0.01% 1152
2021
Q3 		$8K Buy
157
+80
+104% +$4.51K ﹤0.01% 1239
2021
Q2 		$6K Buy
77
+11
+17% +$680 ﹤0.01% 1296
2021
Q1 		$4K Buy
+66
New +$4.42K ﹤0.01% 1352

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCI Wealth Advisors's DNLI Position: Q3 2022 in Review

TCI Wealth Advisors sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 114 shares — an estimated $3K sold.

TCI Wealth Advisors first reported a position in DNLI in Q1 2021 and held it in 6 quarters. The position peaked at $10K in Q1 2022. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

  • TCI Wealth Advisors reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 114 Denali Therapeutics shares in Q3 2022, an estimated $3K.
  • TCI Wealth Advisors first reported a position in Denali Therapeutics in Q1 2021 and held it in 6 quarters.
  • TCI Wealth Advisors's Denali Therapeutics position peaked at $10K in Q1 2022.
  • 200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on TCI Wealth Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.